Miroslava Benešová
The aim of antithrombotic therapy using vitamin K antagonists, new oral anticoagulants, heparins and antiaggregation drugs is an effective prevention and treatment of venous and arterial thromboembolic events simultaneously with an acceptable risk of bleeding. The need of interruption of the antithrombotic treatment due to the planned or acute invasive procedures and due to the bleeding is a persistent problem. This review article focuses on specific situations where it is necessary to interrupt anticoagulant therapy. It covers the various schemes of treatment according to the risk of thromboembolism and bleeding from both the patient and the procedure in accordance with the guidelines of Czech, European and American societies of cardiology and cardiac chest surgery.